Recursion
Contact SalesAI-driven drug discovery platform decoding biology with cellular imaging.
By Tanmay Verma, Founder · Last verified 29 May 2026
7.0k views
Added 7d ago
76/100Safe BetAI-driven drug discovery platform decoding biology with cellular imaging.
By Tanmay Verma, Founder · Last verified 29 May 2026
Affiliate disclosure: We earn a commission when you use our links. Editorial picks are independent. How we choose.
Recursion's platform is for serious pharma R&D teams needing to accelerate target identification and molecule design. Its massive proprietary dataset and automated wet lab are unique assets, but it's not a tool for individual researchers or small biotechs without deep pockets.
Compare with: Recursion vs Quibim, Recursion vs Qualtrics XM, Recursion vs Nimbus Therapeutics
Last verified: May 2026
Recursion stands out for its decade-long investment in proprietary cellular imaging data, now exceeding 50 petabytes, and its fully integrated AI-pharma pipeline. If you're a large pharma company or a well-funded biotech looking to reduce early-stage discovery costs and speed up hit-to-lead timelines, Recursion's platform can model complex biology through its Recursion OS and automated lab. However, it's not for academic labs or startups on a budget; the platform is enterprise-grade with significant licensing costs. Compared to competitors like Insilico Medicine or Exscientia, Recursion's emphasis on cellular phenomics and its partnership with NVIDIA for supercomputing gives it an edge in data generation and processing speed. A real-world caveat: the platform's full potential may only be realized in long-term collaborations, as the AI models require continuous data feedback. For those seeking a turnkey AI tool for chemistry, Recursion may be overkill; for those wanting to de-risk target discovery with massive biological datasets, it's a strong candidate.
Skip Recursion if Skip Recursion if you need a self-service software tool or are an individual researcher without support from a large pharma or biotech organization.
How likely is Recursion to still be operational in 12 months? Based on 6 signals including funding, development activity, and platform risk.
Recursion is an AI-powered drug discovery company that uses cellular imaging and machine learning to decode biology and develop novel treatments. Founded over a decade ago, the company trains AI on images of cells to understand biological disruptions driving disease, aiming to reduce the 90% failure rate of traditional drug discovery. The platform, Recursion OS, integrates proprietary biological and chemical datasets (over 50 petabytes) spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. Key features include an automated wet lab with robotics and computer vision, supercomputer BioHive-2 built with NVIDIA, and a pipeline of potential first-in-class and best-in-class treatments for solid tumors, lymphomas, B-cell malignancies, familial adenomatous polyposis, and hypophosphatasia. Recursion's partnerships with pharmaceutical and technology leaders enhance its AI-driven drug discovery capabilities, positioning it as a top TechBio company.
Tell us what you want to build — we'll match the AI tools that fit your goal, budget & existing stack.
Concrete scenarios for the personas Recursion actually fits — and what changes day-one when you adopt it.
You provide a disease indication; Recursion runs high-content imaging on cellular models, identifies novel targets via the OS, and validates hits in automated wet labs.
Outcome: You receive a list of validated targets with supporting data in weeks, not years.
You share a hit compound; Recursion's generative AI designs analogs, synthesizes them via robotics, and tests them in assays.
Outcome: You obtain optimized lead molecules with improved potency and selectivity within months.
Recursion does not offer a publicly accessible API or self-service platform; access requires a partnership or collaboration. Its automated wet labs are proprietary and not available for external use. The platform's complexity and scale mean it is unsuitable for small-scale or individual projects.
The company stage and team size where Recursion's pricing actually pencils out — and where peers do it cheaper.
Recursion does not publish pricing; it operates through partnerships and collaborations. This model best suits large pharma companies with dedicated R&D budgets. For smaller organizations, the lack of transparent pricing and self-service access makes it impractical compared to options like Atomwise or Cyclica.
How long it actually takes to get something useful out of Recursion — broken out by persona, not the marketing-page minute.
First value (validated target or lead) typically takes 6–12 months, including collaboration agreement, data transfer, and initial experiments. Ongoing experiments can then run weekly.
Common stack mates teams adopt alongside Recursion, with the specific reason each pairing earns its keep.
Used Recursion? Help shape our editorial sentiment research.
© 2026 RightAIChoice. All rights reserved.
Built for the AI community.
Last calculated: May 2026
Designing highly selective small molecule medicines for oncology, immunology, and metabolism.
